Bioniq, a personalized nutrition company, has unveiled its latest innovation: Bioniq Build Your Own. Designed to cater to the estimated 15% of individuals with special health needs, this hyper-personalized supplement solution enables consumers to create tailored formulas addressing allergies, vitamin and mineral intolerances, as well as other unique health requirements.
This launch marks a pivotal step in Bioniq’s mission to reshape the supplements market, an industry projected to grow annually by 6.74% and reach $44.24 billion by 2029. Following the success of Bioniq GO in 2023, the company’s Build Your Own platform represents its most significant advancement yet, particularly as demand from the U.S. market surges.
“Bioniq is the only company capable of offering an extensive list of vitamins, minerals, and phytonutrients in flexible dosages, thanks to our AI-driven approach and innovative granular delivery system,” said Oliver Motisi, Chief Product Officer at Bioniq.
“This unique approach empowers individuals with chronic diagnoses or specific health conditions to create supplement blends tailored to their needs, improving quality of life on a global scale.”
Bioniq Build Your Own enables users to select from over 50 nutrients, either following Bioniq’s data-driven formula recommendations or curating a fully customized blend. The supplements leverage Bioniq’s patented granular dosage form to ensure high bioavailability and efficacy.
The platform is powered by Bioniq’s proprietary AI algorithm, which evaluates users’ blood biomarker data alongside self-reported health metrics, such as height, weight, age, lifestyle and health goals. This process identifies micronutrient imbalances and delivers a tailored supplement solution, alongside daily nutrient support, nutrition consultations and educational resources.
Recent data underscores the effectiveness of Bioniq’s approach:
94% of clients optimized Ferritin levels within 6 months.
86% of clients optimized Zinc levels within 6 months.
82% of clients optimized Vitamin E levels within 6 months.
These findings align with a recent poll revealing that 86% of individuals find the lack of measurable results the most frustrating aspect of traditional supplements.
Bioniq’s user base grew fivefold in 2024, and its products are now sold in over 70 countries. Its success has attracted high-profile partnerships with leading health and sports organizations, including Lanserhof and UFC. The company also recently announced an investment by global football icon Cristiano Ronaldo, raising its valuation to $82 million. This follows a successful Series B round led by HV Capital and Unbound, which raised $15 million to fuel further growth and product development.
“By combining advanced blood biomarker analysis with personalized formulas, Bioniq is not just meeting demand — it’s redefining how people approach their health,” added Motisi.
For more information, visit Bioniq’s website or explore their recent study here.
